Sleep Characteristics, Cognitive Function, Alzheimer’s Disease and Vascular Pathology Biomarkers in Cognitively Unimpaired Older Adults

Overview

Información sobre este estudio

The purpose of this study is to identify the association between untreated OSA and chronic insomnia and their association with cognitive decline, increased Alzheimer's Disease (AD) and vascular pathology.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Age ≥ 60 years old at time of consent.
  • Concurrent enrollment in the Alzheimer’s Disease Research Center (ADRC, Mayo IRB 712-98) and/or Mayo Clinic Study of Aging (MCSA, Mayo IRB 14-004401).
    • Note: Participants may be but are not required to be concurrently enrolled in Brain Amyloid Imaging with Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment and Dementia (PiB, Mayo IRB 08-005553).  
  • Normal cognition to moderate severity Alzheimer’s disease dementia (CDR ≤ 2) or vascular dementia.
  • Participants with mild cognitive impairment or dementia must have a care partner or LAR to assist them with the WP setup and the questionnaires,

Exclusion Criteria:

  • History of or current non-Alzheimer’s or vascular dementia, such as dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), normal pressure hydrocephalus (NPH) dementia or undetermined cause dementia.
  • Major neurological condition (i.e., non-lacunar stroke, TBI, epilepsy, tumor, CNS infection, demyelinating disease, neurodegenerative disease), severe autonomic failure (pure autonomic failure or autonomic neuropathy), major psychiatric disease (i.e., alcohol/drug abuse and schizophrenia),
  • Current treatment of OSA. Diagnosed but untreated OSA is acceptable.
  • Use of short-acting nitrates within 3 hours of the sleep study.
  • Use of selective α1-adrenergic receptor antagonists, for example, tamsulosin (Flomax®), doxazosin (Cardura®), prazosin (Minipress®), and terazosin (Hytrin®) and nonselective α1 and α2 blockers (pentholamine and phenoxybenzamine)
  • Finger deformity that precludes adequate sensor application
  • Placement of a permanent pacemaker
  • Persistent atrial fibrillation or other sustained non-sinus cardiac arrhythmias
  • Severe peripheral vascular disease (e.g., status post stent or by-pass surgery in one of the limbs, faint/absent pulses)
  • Status post bilateral cervical or thoracic sympathectomy
  • Acute lung or heart disease (e.g., decompensated COPD or heart failure).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/29/23.  Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Diego Zaquera Carvalho, M.D., M.S.

Cerrado; inscripción por invitación

¿Qué es esto? (?)
"Close"
El estudio no está abierto para todos los que cumplen con los criterios de elegibilidad, sino solamente para las personas que el equipo del estudio ha invitado a participar.

Contact information:

Alzheimer's Disease Research Center

(507) 284-1324

More information

Publicaciones

Publications are currently not available
.
CLS-20537034

Mayo Clinic Footer